Skip to content

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Semaglutide demonstrates favorable safety profile with 43% reduction in serious adverse events in adults with established ASCVD: a systematic review and meta-analysis of randomized controlled trials

Cardiovascular disease remains the leading cause of mortality worldwide. Semaglutide, a GLP-1 receptor agonist, has shown cardiovascular benefits, but its safety profile, including risks of various adverse events, in adults with established atherosclerotic cardiovascular disease (ASCVD) requires systematic evalua...

K. Keswani, M. Reddy, A. Aslam et al. · 0 citations
Open access Oct 2026

Does initiating SGLT2 inhibitors at an early stage of heart failure admission really reduce cardiovascular mortality and first rehospitalization? A meta-analysis of randomized controlled trials

Acute heart failure (HF) patients are at high risk, especially in the first three months following discharge, when rehospitalizations are 30% common and mortality can be close to 10%. Although sodium-glucose cotransporter-2 (SGLT2) inhibitors are essential for treating heart failure, their benefit when initiated...

N. Shafi, F. Khalid, M. Elshabrawi et al. · 0 citations
Open access Oct 2026

Distal radial access dramatically reduces hemostasis time and bleeding in coronary interventions: a meta-analysis of 7 randomized trials

Transradial access has revolutionized interventional cardiology by reducing vascular complications compared to femoral approaches. However, as novel techniques emerge, comprehensive quantitative synthesis comparing these methodologies remains limited, creating uncertainty regarding the optimal procedural strategy...

K. Keswani, H. Saqib, T. Khan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.